CORCEPT THERAPEUTICS INC Entity-Wide Revenue, Major Customer, Percentage (Deprecated 2013-01-31)
CORCEPT THERAPEUTICS INC (CORT) reported Entity-Wide Revenue, Major Customer, Percentage (Deprecated 2013-01-31) of 98.50% for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-05-08.
Discontinued › Income Statement › Other Income
us-gaap:EntityWideRevenueMajorCustomerPercentage · last filed 2013-05-08
- CORCEPT THERAPEUTICS INC entity-wide revenue, major customer, percentage (deprecated 2013-01-31) for the quarter ending 2013-03-31 was 98.50%.
| Period end | Entity-Wide Revenue, Major Customer, Percentage (Deprecated 2013-01-31) 3 month |
|---|---|
| 2013-03-31 | 98.50% 10-Q · filed 2013-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |